Tryptophan Hydroxylase 1 Drives Glioma Progression by Modulating the Serotonin/L1CAM/NF-κB Signaling Pathway

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2022 Apr 27

PMID 35473609

Authors

Jie Zhang

Zhangchao Guo

Qiangli Xie

Chuanhong Zhong

Xiangyu Gao

Qiumei Yang

Affiliations

Soon will be listed here.

Abstract

Background: Glioma is one of the main causes of cancer-related mortality worldwide and is associated with high heterogeneity. However, the key players determining the fate of glioma remain obscure. In the present study, we shed light on tumor metabolism and aimed to investigate the role of tryptophan hydroxylase 1 (TPH-1) in the advancement of glioma.

Method: Herein, the levels of TPH-1 expression in glioma tissues were evaluated using The Cancer Genome Atlas (TCGA) database. Further, the proliferative characteristics and migration ability of TPH-1 overexpressing LN229/T98G cells were evaluated. Additionally, we performed a cytotoxicity analysis using temozolomide (TMZ) in these cells. We also examined the tumor growth and survival time in a mouse model of glioma treated with chemotherapeutic agents and a TPH-1 inhibitor.

Results: The results of both clinical and experimental data showed that excess TPH-1 expression resulted in sustained glioma progression and a dismal overall survival in these patients. Mechanistically, TPH-1 increased the production of serotonin in glioma cells. The elevated serotonin levels then augmented the NF-κB signaling pathway through the upregulation of the L1-cell adhesion molecule (L1CAM), thereby contributing to cellular proliferation, invasive migration, and drug resistance. In vivo experiments demonstrated potent antitumor effects, which benefited further from the synergistic combination of TMZ and LX-1031.

Conclusion: Taken together, these data suggested that TPH-1 facilitated cellular proliferation, migration, and chemoresistance in glioma through the serotonin/L1CAM/NF-κB pathway. By demonstrating the link of amino acid metabolic enzymes with tumor development, our findings may provide a potentially viable target for therapeutic manipulation aimed at eradicating glioma.

Citing Articles

Amino acid metabolism in glioblastoma pathogenesis, immune evasion, and treatment resistance.

Srivastava S, Anbiaee R, Houshyari M, Laxmi , Sridhar S, Ashique S Cancer Cell Int. 2025; 25(1):89.

PMID: 40082966 PMC: 11908050. DOI: 10.1186/s12935-025-03721-1.

Molecular mechanisms and therapeutic significance of Tryptophan Metabolism and signaling in cancer.

Yan J, Chen D, Ye Z, Zhu X, Li X, Jiao H Mol Cancer. 2024; 23(1):241.

PMID: 39472902 PMC: 11523861. DOI: 10.1186/s12943-024-02164-y.

Navigating glioblastoma complexity: the interplay of neurotransmitters and chromatin.

Romero-Reyes J, Vazquez-Martinez E, Silva C, Molina-Hernandez A, Diaz N, Camacho-Arroyo I Mol Biol Rep. 2024; 51(1):912.

PMID: 39153092 PMC: 11330389. DOI: 10.1007/s11033-024-09853-3.

Role of Serotonergic System in Regulating Brain Tumor-Associated Neuroinflammatory Responses.

Karmakar S, Lal G Methods Mol Biol. 2024; 2761:181-207.

PMID: 38427238 DOI: 10.1007/978-1-0716-3662-6_14.

The Recent Research Progress of NF-κB Signaling on the Proliferation, Migration, Invasion, Immune Escape and Drug Resistance of Glioblastoma.

Shi P, Xu J, Cui H Int J Mol Sci. 2023; 24(12).

PMID: 37373484 PMC: 10298967. DOI: 10.3390/ijms241210337.

References

Silletti S, Yebra M, Perez B, Cirulli V, McMahon M, Montgomery A . Extracellular signal-regulated kinase (ERK)-dependent gene expression contributes to L1 cell adhesion molecule-dependent motility and invasion. J Biol Chem. 2004; 279(28):28880-8. DOI: 10.1074/jbc.M404075200. View

Mohanan V, Temburni M, Kappes J, Galileo D . L1CAM stimulates glioma cell motility and proliferation through the fibroblast growth factor receptor. Clin Exp Metastasis. 2012; 30(4):507-20. DOI: 10.1007/s10585-012-9555-4. View

Reifenberger G, Wirsching H, Knobbe-Thomsen C, Weller M . Advances in the molecular genetics of gliomas - implications for classification and therapy. Nat Rev Clin Oncol. 2016; 14(7):434-452. DOI: 10.1038/nrclinonc.2016.204. View

Wang J, Yan L, Ai P, He Y, Guan H, Wei Z . Observation versus radiotherapy with or without temozolomide in postoperative WHO grade II high-risk low-grade glioma: a retrospective cohort study. Neurosurg Rev. 2020; 44(3):1447-1455. DOI: 10.1007/s10143-020-01326-y. View

Opitz C, Somarribas Patterson L, Mohapatra S, Dewi D, Sadik A, Platten M . The therapeutic potential of targeting tryptophan catabolism in cancer. Br J Cancer. 2019; 122(1):30-44. PMC: 6964670. DOI: 10.1038/s41416-019-0664-6. View

Lieu E, Nguyen T, Rhyne S, Kim J . Amino acids in cancer. Exp Mol Med. 2020; 52(1):15-30. PMC: 7000687. DOI: 10.1038/s12276-020-0375-3. View

Schafer M, Altevogt P . L1CAM malfunction in the nervous system and human carcinomas. Cell Mol Life Sci. 2010; 67(14):2425-37. PMC: 11115577. DOI: 10.1007/s00018-010-0339-1. View

Mohan S, Abdelwahab S, Kamalidehghan B, Syam S, May K, Harmal N . Involvement of NF-κB and Bcl2/Bax signaling pathways in the apoptosis of MCF7 cells induced by a xanthone compound Pyranocycloartobiloxanthone A. Phytomedicine. 2012; 19(11):1007-15. DOI: 10.1016/j.phymed.2012.05.012. View

Gavert N, Conacci-Sorrell M, Gast D, Schneider A, Altevogt P, Brabletz T . L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol. 2005; 168(4):633-42. PMC: 2171754. DOI: 10.1083/jcb.200408051. View

10.

Geismann C, Morscheck M, Koch D, Bergmann F, Ungefroren H, Arlt A . Up-regulation of L1CAM in pancreatic duct cells is transforming growth factor beta1- and slug-dependent: role in malignant transformation of pancreatic cancer. Cancer Res. 2009; 69(10):4517-26. DOI: 10.1158/0008-5472.CAN-08-3493. View

11.

Xu S, Tang L, Li X, Fan F, Liu Z . Immunotherapy for glioma: Current management and future application. Cancer Lett. 2020; 476:1-12. DOI: 10.1016/j.canlet.2020.02.002. View

12.

Masab M, Saif M . Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea. Cancer Chemother Pharmacol. 2017; 80(6):1055-1062. DOI: 10.1007/s00280-017-3462-y. View

13.

Riedle S, Kiefel H, Gast D, Bondong S, Wolterink S, Gutwein P . Nuclear translocation and signalling of L1-CAM in human carcinoma cells requires ADAM10 and presenilin/gamma-secretase activity. Biochem J. 2009; 420(3):391-402. PMC: 2782312. DOI: 10.1042/BJ20081625. View

14.

Pai V, Marshall A, Hernandez L, Buckley A, Horseman N . Altered serotonin physiology in human breast cancers favors paradoxical growth and cell survival. Breast Cancer Res. 2009; 11(6):R81. PMC: 2815543. DOI: 10.1186/bcr2448. View

15.

Altevogt P, Doberstein K, Fogel M . L1CAM in human cancer. Int J Cancer. 2015; 138(7):1565-76. DOI: 10.1002/ijc.29658. View

16.

Balakrishna P, George S, Hatoum H, Mukherjee S . Serotonin Pathway in Cancer. Int J Mol Sci. 2021; 22(3). PMC: 7865972. DOI: 10.3390/ijms22031268. View

17.

Hoesel B, Schmid J . The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer. 2013; 12:86. PMC: 3750319. DOI: 10.1186/1476-4598-12-86. View

18.

Pavlova N, Thompson C . The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016; 23(1):27-47. PMC: 4715268. DOI: 10.1016/j.cmet.2015.12.006. View

19.

Li T, Fu B, Zhang X, Zhou Y, Yang M, Cao M . Overproduction of Gastrointestinal 5-HT Promotes Colitis-Associated Colorectal Cancer Progression via Enhancing NLRP3 Inflammasome Activation. Cancer Immunol Res. 2021; 9(9):1008-1023. DOI: 10.1158/2326-6066.CIR-20-1043. View

20.

Gwynne W, Shakeel M, Girgis-Gabardo A, Hassell J . The Role of Serotonin in Breast Cancer Stem Cells. Molecules. 2021; 26(11). PMC: 8198186. DOI: 10.3390/molecules26113171. View